Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623888957> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2623888957 endingPage "TPS1109" @default.
- W2623888957 startingPage "TPS1109" @default.
- W2623888957 abstract "TPS1109 Background: Inhibition of CDK4 in preclinical models, demonstrated efficacy in HER2+ breast cancer and enhanced activity of HER2-targeted therapy suggesting a crosstalk between HER2 signaling and the cyclin D/CDK4 signaling pathway in which CDK4 & CDK6 inhibitors may re-sensitize resistant tumors to HER2 blockade.Abemaciclib is a selective inhibitor of CDK4 & CDK6 inhibitor that demonstrates single-agent anti-tumor activity on a continuous dosing schedule in women with hormone receptor positive (HR+) advanced breast cancer. Triple regimens with abemaciclib have been tolerable. Methods: monarcHER is an ongoing Phase 2, open-label, study in postmenopausal women with HR+, HER2+ locally advanced or metastatic breast cancer. Eligible patients (pts) are those previously treated with ≥2 HER2-directed therapies in advanced disease setting; T-DM1 and a taxane in any disease setting; no prior treatment with fulvestrant or any CDK4 & CDK6 inhibitor or with ECOG PS ≤1; LVEF ≥50%; no visceral crisis and no CNS metastases that are untreated, symptomatic or requiring steroids. Pts are randomized 1:1:1 to Arm A (abemaciclib [150mg PO Q12H] plus trastuzumab [IV infusion Q3 weeks] plus fulvestrant [IM injection on D1, 15, 29 then Q4 weeks]), Arm B (abemaciclib plus trastuzumab), or Arm C (trastuzumab plus SOC single-agent chemotherapy of physician’s choice); stratified based on number of prior systemic regimens (excluding single agent endocrine therapy) and disease status (measurable vs nonmeasurable). The primary objective evaluates investigator-assessed progression-free survival (PFS). Secondary objectives include overall survival, objective response rate, duration of response, disease control rate, clinical benefit rate, safety and tolerability, efficacy, health outcomes and pharmacokinetics. Analysis is planned at 165 PFS events, providing ≥80% power to detect superiority of Arm A and Arm B over Arm C, assuming a hazard ratio of 0.67 at a one-sided alpha of 0.10. First pt visit occurred in May 2016; with a target enrollment of 225 pts. Contact information: 1-877-CTLILLY (1-877-285-4559) Clinical trial information: NCT02675231." @default.
- W2623888957 created "2017-06-15" @default.
- W2623888957 creator A5001814176 @default.
- W2623888957 creator A5012824041 @default.
- W2623888957 creator A5033578877 @default.
- W2623888957 creator A5059827500 @default.
- W2623888957 creator A5069056507 @default.
- W2623888957 date "2017-05-20" @default.
- W2623888957 modified "2023-10-05" @default.
- W2623888957 title "A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive, HER2-positive advanced breast cancer (monarcHER)." @default.
- W2623888957 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps1109" @default.
- W2623888957 hasPublicationYear "2017" @default.
- W2623888957 type Work @default.
- W2623888957 sameAs 2623888957 @default.
- W2623888957 citedByCount "3" @default.
- W2623888957 countsByYear W26238889572018 @default.
- W2623888957 countsByYear W26238889572019 @default.
- W2623888957 countsByYear W26238889572020 @default.
- W2623888957 crossrefType "journal-article" @default.
- W2623888957 hasAuthorship W2623888957A5001814176 @default.
- W2623888957 hasAuthorship W2623888957A5012824041 @default.
- W2623888957 hasAuthorship W2623888957A5033578877 @default.
- W2623888957 hasAuthorship W2623888957A5059827500 @default.
- W2623888957 hasAuthorship W2623888957A5069056507 @default.
- W2623888957 hasConcept C121608353 @default.
- W2623888957 hasConcept C126322002 @default.
- W2623888957 hasConcept C143998085 @default.
- W2623888957 hasConcept C197934379 @default.
- W2623888957 hasConcept C2775930923 @default.
- W2623888957 hasConcept C2777511904 @default.
- W2623888957 hasConcept C2778375690 @default.
- W2623888957 hasConcept C2779744173 @default.
- W2623888957 hasConcept C2779786085 @default.
- W2623888957 hasConcept C2780482068 @default.
- W2623888957 hasConcept C530470458 @default.
- W2623888957 hasConcept C71924100 @default.
- W2623888957 hasConcept C84606932 @default.
- W2623888957 hasConceptScore W2623888957C121608353 @default.
- W2623888957 hasConceptScore W2623888957C126322002 @default.
- W2623888957 hasConceptScore W2623888957C143998085 @default.
- W2623888957 hasConceptScore W2623888957C197934379 @default.
- W2623888957 hasConceptScore W2623888957C2775930923 @default.
- W2623888957 hasConceptScore W2623888957C2777511904 @default.
- W2623888957 hasConceptScore W2623888957C2778375690 @default.
- W2623888957 hasConceptScore W2623888957C2779744173 @default.
- W2623888957 hasConceptScore W2623888957C2779786085 @default.
- W2623888957 hasConceptScore W2623888957C2780482068 @default.
- W2623888957 hasConceptScore W2623888957C530470458 @default.
- W2623888957 hasConceptScore W2623888957C71924100 @default.
- W2623888957 hasConceptScore W2623888957C84606932 @default.
- W2623888957 hasIssue "15_suppl" @default.
- W2623888957 hasLocation W26238889571 @default.
- W2623888957 hasOpenAccess W2623888957 @default.
- W2623888957 hasPrimaryLocation W26238889571 @default.
- W2623888957 hasRelatedWork W2019965686 @default.
- W2623888957 hasRelatedWork W2092771806 @default.
- W2623888957 hasRelatedWork W2139977268 @default.
- W2623888957 hasRelatedWork W2163622510 @default.
- W2623888957 hasRelatedWork W2767256081 @default.
- W2623888957 hasRelatedWork W3006282423 @default.
- W2623888957 hasRelatedWork W3189331974 @default.
- W2623888957 hasRelatedWork W4281675214 @default.
- W2623888957 hasRelatedWork W4283528480 @default.
- W2623888957 hasRelatedWork W4295817034 @default.
- W2623888957 hasVolume "35" @default.
- W2623888957 isParatext "false" @default.
- W2623888957 isRetracted "false" @default.
- W2623888957 magId "2623888957" @default.
- W2623888957 workType "article" @default.